The CEO & Chairman of the Board of Inovalon (NASDAQ: INOV) is Buying Shares

By George MacDonald

Today, the CEO & Chairman of the Board of Inovalon (NASDAQ: INOV), Keith Dunleavy, bought shares of INOV for $500.4k.

Keith Dunleavy increased his holding by 129.61%.

Based on Inovalon`s latest earnings report from December 31, the company posted quarterly revenue of $120.6M and quarterly net profit of $16.05M. In comparison, last year the company earned revenue of $93.63M and had a net profit of $13.76M. The company has a one year high of $29 and a one year low of $15.12. INOV’s market cap is $2.54B and the company has a P/E ratio of 37.22%.

Based on 4 analyst ratings, the analyst consensus is Hold with an average price target of $18.67, reflecting a -10.3% downside. Five different firms, including Goldman Sachs and KeyBanc, currently also have a Buy rating on the stock.

Looking at blogger coverage of INOV, there is a 100% Bullish tendency on the stock, in relation to a 75% average bullish tendency within the Technology sector.

Over the last 3 months, the insider sentiment on Inovalon has been negative based on 37 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Inovalon Holdings, Inc. operates as a technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and improvement in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Its powerful platform drives high-value impact, improving quality and economics for health plans, hospitals, physicians, patients, pharmaceutical companies, and researchers. Inovalon Holdings was founded on September 11, 2014 and is headquartered in Bowie, MD.